GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hypha Labs Inc (OTCPK:FUNI) » Definitions » Cyclically Adjusted Price-to-FCF

FUNI (Hypha Labs) Cyclically Adjusted Price-to-FCF : (As of Jan. 19, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Hypha Labs Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Hypha Labs Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Hypha Labs's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hypha Labs Cyclically Adjusted Price-to-FCF Chart

Hypha Labs Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hypha Labs Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Hypha Labs's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Hypha Labs's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hypha Labs's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Hypha Labs's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Hypha Labs's Cyclically Adjusted Price-to-FCF falls into.



Hypha Labs Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Hypha Labs's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Hypha Labs's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.004/133.0289*133.0289
=-0.004

Current CPI (Sep. 2024) = 133.0289.

Hypha Labs Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 -0.276 99.070 -0.371
201503 -0.181 99.621 -0.242
201506 -0.064 100.684 -0.085
201509 -0.064 100.392 -0.085
201512 -0.027 99.792 -0.036
201603 -0.012 100.470 -0.016
201606 -0.010 101.688 -0.013
201609 0.003 101.861 0.004
201612 0.001 101.863 0.001
201703 -0.005 102.862 -0.006
201706 -0.007 103.349 -0.009
201709 -0.006 104.136 -0.008
201712 0.001 104.011 0.001
201803 -0.003 105.290 -0.004
201806 -0.008 106.317 -0.010
201809 0.001 106.507 0.001
201812 -0.009 105.998 -0.011
201903 -0.007 107.251 -0.009
201906 -0.004 108.070 -0.005
201909 -0.003 108.329 -0.004
201912 -0.005 108.420 -0.006
202003 -0.007 108.902 -0.009
202006 -0.003 108.767 -0.004
202009 -0.001 109.815 -0.001
202012 -0.001 109.897 -0.001
202103 0.000 111.754 0.000
202106 -0.001 114.631 -0.001
202109 0.000 115.734 0.000
202112 -0.002 117.630 -0.002
202203 0.000 121.301 0.000
202206 0.000 125.017 0.000
202209 0.000 125.227 0.000
202212 0.000 125.222 0.000
202303 -0.002 127.348 -0.002
202306 0.002 128.729 0.002
202309 0.001 129.860 0.001
202312 0.001 129.419 0.001
202403 -0.001 131.776 -0.001
202406 -0.005 132.554 -0.005
202409 -0.004 133.029 -0.004

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Hypha Labs  (OTCPK:FUNI) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Hypha Labs Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Hypha Labs's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Hypha Labs Business Description

Traded in Other Exchanges
N/A
Address
5940 S. Rainbow Boulevard, Las Vegas, NV, USA, 89118
Hypha Labs Inc has developed technology that quickly cultivates the mycelium root structures of psilocybin mushrooms and other functional mushroom's mycelium into a natural product. This product has an exact, consistent potency containing all the natural compounds found in these fungi. Typically, it takes 6-8 weeks to fully grow mushrooms, and using Hyphalabs technology the production of the active ingredient is only 7-10 days. This natural product solves the dosing issue created by having to use whole mushrooms currently. The product is tasteless and gentler on the stomach and can be used sublingually for fast-acting results. The product allows the consumer to produce measurable active ingredients at home for mental and physical benefits.
Executives
A Stone Douglass director 10200 WILLOW CREEK ROAD, SAN DIEGO CA 92131
Edmond Defrank director 19360 RINALDI STREET, #448, NORTHRIDGE CA 91326
Kyle Remenda officer: Chief Executive Officer 111-2532 SHORELINE DRIVE, LAKE COUNTRY A1 V4V2R6
Dennis Hartmann director 1600 CAMDEN AVENUE, NO. 103, LOS ANGELES CA 90025
Bruce I Raben director 430 VICTORIA TERRACE, RIDGEFIELD NJ 7657
Cindy Sue Orser director 4507 APPLE WAY, BOULDER CO 80301
Alfredo Axtmayer director 287 PAYNE DRIVE, CHESHIRE CT 06410
Joseph J Bianco director 611 BROADWAY,, SUITE 307, NEW YORK NY 10012
Todd A Peterson officer: Chief Financial Officer 3608 MALLARDWOOD DRIVE, LAS VEGAS NV 89129
Joe D Tanner director 28720 ROADSIDE DRIVE, SUITE 128, AGOURA HILLS CA 91301
Raw Alternative, Llc 10 percent owner 16030 VENTURA BLVD. SUITE 380, ENCINO CA 91436
Todd Denkin director, officer: President C/O PHOTOTRON, INC., 20259 VENTURA BLVD., WOODLAND HILLS CA 91364
Barbee Denny Barbee 10 percent owner 3105 EAST CENTRAL, #114, WICHITA KS 67214
Eric Stoppenhagen director, 10 percent owner, officer: CFO 8908 SPLITARROW DRIVE, AUSTIN TX 78717